12:27 PM EST, 11/15/2024 (MT Newswires) -- Arbutus Biopharma ( ABUS ) said Friday new data from phase 2a trial of imdusiran followed by Barinthus Biotherapeutics' ( BRNS ) VTP-300 plus a low dose of nivolumab in chronic hepatitis B patients showed "promising" results.

The preliminary data showed that trial participants who received the regimen experienced increased rates of HBsAg loss compared with those who received imdusiran and VTP-300 or placebo.

The data were presented at the Liver Meeting 2024 of the American Association for the Study of Liver Diseases.

Arbutus shares were down 2% in recent trading, while those of Barinthus slid nearly 19%.

Price: 3.56, Change: -0.07, Percent Change: -2.07